Abstract
The discovery of the first oral anticoagulant, warfarin, was a milestone in anticoagulation. Warfarin's well-known limitations, however, have led to the recent development of more effective anticoagulants. The rapidly growing list of these drugs, however, presents a challenge to endoscopists who must treat patients on these sundry medications. This review is intended to summarize the pharmacological highlights of new anticoagulants, with particular attention to suggested "best-practice" recommendations for the withholding of these drugs before endoscopic procedures.
MeSH terms
-
Administration, Oral
-
Anticoagulants* / administration & dosage
-
Anticoagulants* / adverse effects
-
Anticoagulants* / classification
-
Anticoagulants* / pharmacokinetics
-
Blood Loss, Surgical / prevention & control*
-
Drug Interactions
-
Drug Monitoring
-
Endoscopy / adverse effects*
-
Endoscopy / methods
-
Humans
-
Patient Safety
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / classification
-
Platelet Aggregation Inhibitors / pharmacokinetics
-
Product Surveillance, Postmarketing
-
Risk Adjustment
-
Thromboembolism / drug therapy*
-
Withholding Treatment
Substances
-
Anticoagulants
-
Platelet Aggregation Inhibitors